Behçet’s syndrome - Pipeline Insight, 2021

DelveInsight’s, “Behçet’s syndrome - Pipeline Insight, 2021,” report provides comprehensive insights about 3+ companies and 3+ pipeline drugs in Behçet’s syndrome pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered
• Global coverage

Behçet’s syndrome Understanding
Behçet’s syndrome: Overview
Behçet’s syndrome is a rare multisystem inflammatory disorder characterized by ulcers affecting the mouth and genitals, various skin lesions, and abnormalities affecting the eyes. Symptoms include mucous membrane lesions of the mouth (canker sores) and genitals (ulcers) that tend to disappear and recur spontaneously. Inflammation of the eyes (anterior uveitis, posterior uveitis, or panuveitis) also affects individuals with Behçet’s syndrome. Additional systems of the body may also be affected including the joints, blood vessels, central nervous system, and/or digestive tract. The exact cause of Behçet’s syndrome is unknown.

""Behçet’s syndrome - Pipeline Insight, 2021"" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Behçet’s syndrome pipeline landscape is provided which includes the disease overview and Behçet’s syndrome treatment guidelines. The assessment part of the report embraces, in depth Behçet’s syndrome commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Behçet’s syndrome collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights
• The companies and academics are working to assess challenges and seek opportunities that could influence Behçet’s syndrome R&D. The therapies under development are focused on novel approaches to treat/improve Behçet’s syndrome.

Behçet’s syndrome Emerging Drugs Chapters
This segment of the Behçet’s syndrome report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Behçet’s syndrome Emerging Drugs
• Hemay005: Tianjin Hemay Pharmaceutical
Hemay005 is an orally available Type 4 cyclic nucleotide phosphodiesterase inhibitor. . The company is conducting Phase II study to evaluate the efficacy and safety of Hemay005 in the treatment of Behçet Disease.

• Canakinumab: Novartis
Canakinumab is a human monoclonal IgG1 that selectively neutralizes IL-1β, inhibiting its binding to IL-1RI and all cytokine-dependent signaling pathways. This results in the suppression of inflammation in patients with disorders of autoimmune origin.
Further product details are provided in the report……..

Behçet’s syndrome: Therapeutic Assessment
This segment of the report provides insights about the different Behçet’s syndrome drugs segregated based on following parameters that define the scope of the report, such as:
• Major Players in Behçet’s syndrome
There are approx. 3+ key companies which are developing the therapies for Behçet’s syndrome. The companies which have their Behçet’s syndrome drug candidates in the most advanced stage, i.e. phase II include, Tianjin Hemay Pharmaceutical.

• Phases
DelveInsight’s report covers around 3+ products under different phases of clinical development like
• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

• Route of Administration
Behçet’s syndrome pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
• Oral
• Parenteral
• intravenous
• Subcutaneous
• Topical.
• Molecule Type

Products have been categorized under various Molecule types such as
• Monoclonal Antibody
• Peptides
• Polymer
• Small molecule
• Gene therapy
• Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Behçet’s syndrome: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Behçet’s syndrome therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Behçet’s syndrome drugs.

Behçet’s syndrome Report Insights
• Behçet’s syndrome Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

Behçet’s syndrome Report Assessment
• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

Key Questions
Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Behçet’s syndrome drugs?
• How many Behçet’s syndrome drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Behçet’s syndrome?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Behçet’s syndrome therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Behçet’s syndrome and their status?
• What are the key designations that have been granted to the emerging drugs?

Key Players
• Tianjin Hemay Pharmaceutical
• Actelion Pharmaceuticals
• Novartis
• Silk Road Therapies, Inc.

Key Products
• Hemay005
• Bosentan
• Canakinumab